BioSpace News Archive

MediciNova, Inc. today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabetes Federation (IDF) World Diabetes Congress 2022 held online December 5 - 8, 2022.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the pricing of an underwritten public offering of 6,818,182 shares of its common stock.

OKYO Pharma Limited announces, that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a secondary public offering of its American Depositary Shares, each of which will represent 65 of the Company’s ordinary shares of no par value each in the United States.

ADAMA Ltd., a leading global crop protection company, announced the acquisition of AgriNova New Zealand, Ltd – known as Grochem New Zealand.

Mainz Biomed NV announced that it has received approval from an independent Institutional Review Board for the protocol ReconAAsense, the Company’s U.S. pivotal study to evaluate the clinical performance of its highly efficacious and easy-to-use detection test for colorectal cancer.

ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer cell therapies to cure patients with cancer, announced the appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer.

Natera, Inc., a global leader in cell-free DNA testing, announced the publication in Prenatal Diagnosis of a clinical experience study in twin pregnancies featuring its Panorama single nucleotide polymorphism -based noninvasive prenatal test.

Achilles Therapeutics plc today presented an encouraging interim Phase I/IIa update on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma at the ESMO Immuno-Oncology Congress 2022 (ESMO IO).

F-star Therapeutics, Inc. today announced new clinical data from its potentially best-in-class clinical asset FS222, a CD137/PD-L1 targeting tetravalent bispecific antibody.

Pivotal Phase 3 Trial Completed Enrollment Ahead of Schedule Enabling Topline Data Readout and NDA Filing in 2024.